Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination
ADMET and DMPK · 09.08.2026 · 14
DOI: 10.5599/admet.3437 ↗Kurz gefasst
Fachartikel in der Zeitschrift ADMET and DMPK, online erschienen am 09.08.2026. Verfasst von Pooja Das Manjulabhai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Sahrdaya College of Engineering and Technology, Affiliated to APJ Abdul Kalam Technological University, Kodakara, Thriss…. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: APJ Abdul Kalam Technological University.
Abstract (Originalsprache)
Background and purpose: Erlotinib (ERL), a first-generation epidermal growth factor receptor tyrosine kinase inhibitor drug that is used in non-small cell lung cancer treatment, requires precise therapeutic drug monitoring owing to its narrow therapeutic window and significant inter-patient pharmacokinetic variability; existing chromatographic methods, while robust, are resource-intensive and incompatible with point-of-care settings, necessitating the development of simpler, cost-effective electroanalytical alternatives. Experimental approach: A titanium dioxide nanoparticle-modified screen-printed electrode (TiO₂NP@SPE) was fabricated via a facile single-step modification and comprehensively characterized by scanning electron microscopy - energy dispersive X-ray Analysis, Fourier transform infrared spectroscopy, X-ray diffraction and electrochemical impedance spectroscopy; electrochemical performance was evaluated by cyclic voltammetry and differential pulse voltammetry, and analytical validation was performed in human serum using the standard addition method. Key results: The TiO₂NP@SPE demonstrated markedly enhanced electron transfer kinetics over the bare SPE, yielding a well-defined linear response with a competitive limit of detection, high sensitivity, and intra- and inter-day serum recoveries within acceptable precision limits, alongside excellent selectivity against physiologically relevant interferents and structurally related anticancer agents. Conclusion: This work developed a disposable screen-printed electrode sufficient to achieve sensitive, selective, and accurate quantification of ERL in human serum using TiO₂NP@SPE as a promising, clinically translatable platform for point-of-care therapeutic drug monitoring in oncology; future efforts should address the elevated detection limit relative to the bare electrode and extend validation to real patient plasma samples to fully confirm clinical applicability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotechnology, Sahrdaya College of Engineering and Technology, Affiliated to APJ Abdul Kalam Technological University, Kodakara, Thrissur, Kerala, India.
ORCID-Profile: Pooja Das Manjulabhai, Sruthi Mundangadan, Maria Paul, Srinivedha Lal, Namitha Ramalal, Mariya Anto, Dhanya Gangadharan
Förderung
- APJ Abdul Kalam Technological University
Zitieren
APA
Manjulabhai, P. D., Mundangadan, S., Paul, M., Lal, S., Ramalal, N., Anto, M., & Gangadharan, D. (2026). Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination. ADMET and DMPK, 14. https://doi.org/10.5599/admet.3437
Vancouver
Manjulabhai PD, Mundangadan S, Paul M, Lal S, Ramalal N, Anto M, et al. Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination. ADMET and DMPK. 2026;14. doi:10.5599/admet.3437
BibTeX
@article{Manjulabhai2026,
author = {Manjulabhai, Pooja Das and Mundangadan, Sruthi and Paul, Maria and Lal, Srinivedha and Ramalal, Namitha and Anto, Mariya and Gangadharan, Dhanya},
title = {Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination},
journal = {ADMET and DMPK},
year = {2026},
volume = {14},
doi = {10.5599/admet.3437}
}
EUVIMED